LIDODERM will be present at the following conventions and conferences:

PRI-MED New York
August 27, 2009 - August 30, 2009
New York, NY
More Information

American Academy of Pain Management
October 8, 2009 - October 11, 2009
Phoenix, AZ
More Information

American Academy of Family Physicians
October 15, 2009 - October 17, 2009
Boston, MA
More Information

American Academy of Physical Medicine and Rehab
October 22, 2009 - October 25, 2009
Austin, TX
More Information

American Osteopathic Association
November 1, 2009 - November 5, 2009
New Orleans, LA
More Information

PRI-MED East
November 12, 2009 - November 15, 2009
Boston, MA
More Information

PRI-MED Mid Atlantic
December 2, 2009 - December 5, 2009
Baltimore, MD
More Information

PRI-MED West
December 4, 2009 – December 5, 2009
Anaheim, CA
More Information

Please note: This list is subject to change without notice.

Patient Profiles
Read the profiles and hear the stories of real LIDODERM patients
Learn More
Signup
Get the latest information on LIDODERM or request samples!
Learn More
Sales Representative
If you would like to talk to a sales representative about LIDODERM, please submit a request online or call 800-462-3636 to find the nearest representative to your office
Submit a Request Online

Important Safety Information

LIDODERM® (lidocaine patch 5%) is indicated for relief of pain associated with post-herpetic neuralgia. Apply only to intact skin.

LIDODERM is contraindicated in patients with a history of sensitivity to local anesthetics (amide type) or any product component.

Even a used LIDODERM patch contains a large amount of lidocaine (at least 665 mg). The potential exists for a small child or pet to suffer serious adverse effects from chewing or ingesting a new or used LIDODERM patch, although the risk with this formulation has not been evaluated. It is important for patients to store and dispose of LIDODERM out of reach of children, pets, and others.

Excessive dosing, such as applying LIDODERM to larger areas or for longer than the recommended wearing time, could result in increased absorption of lidocaine and high blood concentrations leading to serious adverse effects.

Avoid contact of LIDODERM with the eye. If contact occurs, immediately wash the eye with water or saline and protect it until sensation returns. Avoid the use of external heat sources as this has not been evaluated and may increase plasma lidocaine levels.

Patients with severe hepatic disease are at greater risk of developing toxic blood concentrations of lidocaine, because of their inability to metabolize lidocaine normally. LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. LIDODERM should also be used with caution in pregnant (including labor and delivery) or nursing mothers.

Allergic reactions, although rare, can occur.

During or immediately after LIDODERM treatment, the skin at the site of application may develop blisters, bruising, burning sensation, depigmentation, dermatitis, discoloration, edema, erythema, exfoliation, irritation, papules, petechia, pruritus, vesicles, or may be the locus of abnormal sensation. These reactions are generally mild and transient, resolving spontaneously within a few minutes to hours. Other reactions may include dizziness, headache and nausea.

When LIDODERM is used concomitantly with local anesthetic products, the amount absorbed from all formulations must be considered.

Immediately discard used patches or remaining unused portions of cut patches in household trash in a manner that prevents accidental application or ingestion by children, pets, or others.

Before prescribing LIDODERM, please refer to the full Prescribing Information.